Sunil Shaunak argues that pharmaceuticals could, and should, build social capital.
Arguing that the twin risks of rampant infectious disease and resistance to antibiotics represent a grave threat to our future, Sunil makes the case for ethical pharmaceuticals. Sunil's own background bridges the gap between academia and the pharmaceutical industry, and from this vantage point he has grown concerned that while the public sector puts up the initial financial capital, the return is often in purely financial terms, diminishing our shared social capital.
Producer: Giles Edwards.